Jpmorgan Chase & CO G1 Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$2.2 - $4.98 $73,931 - $167,352
-33,605 Reduced 61.51%
21,029 $47,000
Q1 2024

May 10, 2024
BUY
$2.1 - $4.83 $114,206 - $262,674
54,384 Added 21753.6%
54,634 $236,000
Q4 2023

Feb 12, 2024
SELL
$1.12 - $3.73 $10,203 - $33,980
-9,110 Reduced 97.33%
250 $0
Q3 2023

Nov 14, 2023
SELL
$1.22 - $2.67 $2.57 Million - $5.62 Million
-2,106,513 Reduced 99.56%
9,360 $13,000
Q2 2023

Aug 11, 2023
SELL
$2.46 - $3.14 $82,786 - $105,670
-33,653 Reduced 1.57%
2,115,873 $5.27 Million
Q1 2023

May 11, 2023
BUY
$2.57 - $8.16 $292,733 - $929,456
113,904 Added 5.6%
2,149,526 $5.76 Million
Q4 2022

Feb 13, 2023
SELL
$5.19 - $13.5 $42,303 - $110,038
-8,151 Reduced 0.4%
2,035,622 $11.1 Million
Q3 2022

Nov 14, 2022
SELL
$5.17 - $16.99 $442,944 - $1.46 Million
-85,676 Reduced 4.02%
2,043,773 $25.5 Million
Q2 2022

Aug 11, 2022
BUY
$4.04 - $8.51 $128,051 - $269,732
31,696 Added 1.51%
2,129,449 $10.5 Million
Q1 2022

May 11, 2022
SELL
$7.6 - $11.02 $349,075 - $506,159
-45,931 Reduced 2.14%
2,097,753 $15.9 Million
Q4 2021

Feb 10, 2022
SELL
$10.16 - $16.17 $975,309 - $1.55 Million
-95,995 Reduced 4.29%
2,143,684 $21.9 Million
Q3 2021

Nov 12, 2021
BUY
$13.16 - $22.47 $29.5 Million - $50.3 Million
2,239,679 New
2,239,679 $30.1 Million

Others Institutions Holding GTHX

# of Institutions
6
Shares Held
3.55M
Call Options Held
11.7K
Put Options Held
0
View Full List

About G1 Therapeutics, Inc.

GTHX Quotes by TradingView
  • Ticker GTHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,746,800
  • Market Cap $306M
  • Description
  • G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...
More about GTHX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email